medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-29-50-55medalphabet-4047Research ArticleСтатьиОфтальмологические проявления системной красной волчанки: влияние аутоиммунного воспаленияOphthalmologic manifestations of systemic lupus erythematosus: the effect of autoimmune inflammationhttps://orcid.org/0000-0001-5127-611XСпицинаС. С.SpitsinaS. S.

Светлана Сергеевна Спицина, м. н. с., ассистент

клинико-биохимическая лаборатория; ВПТ; кафедра госпитальной терапии

Волгоград

Svetlana S. Spitsina, junior research, Assistant

Clinical biochemistry Laboratory; Hospital therapy department

Volgograd

ssspitsina@mail.ruhttps://orcid.org/0000-0002-0438-8554ШиловаЛ. Н.ShilovaL. N.

Людмила Николаевна Шилова, д. м. н., доцент, зав. кафедрой

ВПТ; кафедра госпитальной терапии

Волгоград

Ludmila N. Shilova, DM Sci (habil.), assistant professor, head of Dept

Hospital Therapy Dept

Volgograd

ludshilova@mail.ruhttps://orcid.org/0000-0003-0373-5072МозговаяЕ. Э.MozgovayaE. E.

Елена Эдуардовна Мозговая, к. м. н., в. н. с.

клинико-биохимическая лаборатория

Волгоград

Elena E. Mozgovaya, PhD Med, leading researcher

Clinical Biochemistry Laboratory

Volgograd

nauka@pebma.orghttps://orcid.org/0000-0002-5316-0185БединаС. А.BedinaS. A.

Светлана Александровна Бедина, к. м. н., с. н. с., доцент

клинико-биохимическая лаборатория; кафедра клинической лабораторной диагностики

Волгоград

Svetlana A. Bedina, PhD Med, senior researcher, assistant professor

Clinical biochemistry Laboratory; Clinical laboratory Diagnostics Dept

Volgograd

clinicalbiochemistry@yandex.ruhttps://orcid.org/0000-0002-1627-8483ТрофименкоА. С.TrofimenkoA. S.

Андрей Степанович Трофименко, к. м. н., зав. лабораторией

клинико-биохимическая лаборатория

Волгоград

Andrei S. Trofimenko, PhD Med, head of Laboratory

Clinical Biochemistry Laboratory

Volgograd

a.s.trofimenko@mail.ruФГБНУ «Научно-исследовательский институт клинической и экспериментальной ревматологии имени А. Б. Зборовского»; ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииРоссияA. B. Zborovsky Research Institute of Clinical and Experimental Rheumatology; Volgograd State Medical UniversityRussian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииРоссияVolgograd State Medical UniversityRussian FederationФГБНУ «Научно-исследовательский институт клинической и экспериментальной ревматологии имени А. Б. Зборовского»РоссияA. B. Zborovsky Research Institute of Clinical and Experimental RheumatologyRussian Federation202412122024029Ревматология в общей врачебной практике (2)5055Copyright © Спицина С.С., Шилова Л.Н., Мозговая Е.Э., Бедина С.А., Трофименко А.С., 20242024Спицина С.С., Шилова Л.Н., Мозговая Е.Э., Бедина С.А., Трофименко А.С.Spitsina S.S., Shilova L.N., Mozgovaya E.E., Bedina S.A., Trofimenko A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4047

   Системная красная волчанка (СКВ) – мультисистемное аутоиммунное заболевание неустановленной этиологии с гетерогенными клиническими проявлениями. До трети больных СКВ имеют различные офтальмологические симптомы. Поражения глаз могут быть начальными признаками СКВ и приводить к тяжелым осложнениям, включая потерю зрения. Офтальмологические проявления часто связаны со степенью активности системного воспаления. Сухой кератоконъюнктивит, или вторичный синдром Шегрена, является наиболее частым поражением глаз при СКВ. Эписклерит и склерит встречаются реже, однако они могут быть первыми признаками заболевания. Односторонняя или чаще двусторонняя ретинопатия, связанная с васкулитом сосудов сетчатки, может являться причиной утраты зрения различной степени тяжести. На фоне длительного применения препаратов, используемых в настоящее время для лечения СКВ, возникает ряд нежелательных офтальмологических явлений: задняя субкапсулярная катаракта и вторичная открытоугольная глаукома при использовании глюкокортикостероидов, ретинопатии – в случаях продолжительного приема гидроксихлорохина. Побочные эффекты других иммуносупрессивных и генно-инженерных биологических препаратов до сих пор плохо изучены. Всем пациентам с СКВ рекомендуется проводить регулярные офтальмологические осмотры.

   Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of unknown etiology with heterogeneous clinical manifestations. One third of patients with SLE have various ophthalmologic symptoms. Eye lesions may be the initial signs of SLE and lead to severe complications, including vision loss. Ophthalmologic manifestations are often associated with the degree of activity of systemic inflammation. Dry keratoconjunctivitis, or secondary Sjogren's syndrome, is the most common ophthalmologic manifestation of SLE. Episcleritis and scleritis are less common, but they can be the first signs of SLE. Unilateral or more often bilateral retinopathy associated with retinal vasculitis can cause visual loss of varying severity. A number of adverse ophthalmologic events occur on the background of long-term use of drugs used currently for the treatment of SLE: posterior subcapsular cataract and secondary open-angle glaucoma when using glucocorticosteroids, retinopathies – in cases of long-term use of hydroxychloroquine. The side effects of other immunosuppressive and biological agents are still poorly understood. Regular ophthalmologic examinations are recommended for all patients with SLE.

системная красная волчанкаофтальмологические проявленияофтальмологические нежелательные явленияsystemic lupus erythematosusоphthalmic manifestationsоcular adverse eventsReferencesHysa E, Cutolo CA, Gotelli E, Paolino S, Cimmino MA, Pacini G, Pizzorni C, Sulli A, Smith V, Cutolo M. Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system. Autoimmun Rev. 2021 May; 20 (5): 102796. DOI: 10.1016/j.autrev.2021.102796Hysa E, Cutolo CA, Gotelli E, Paolino S, Cimmino MA, Pacini G, Pizzorni C, Sulli A, Smith V, Cutolo M. Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system. Autoimmun Rev. 2021 May; 20 (5): 102796. DOI: 10.1016/j.autrev.2021.102796Luboń W, Luboń M, Kotyla P, Mrukwa-Kominek E. Understanding Ocular Findings and Manifestations of Systemic Lupus Erythematosus: Update Review of the Literature. Int J. Mol Sci. 2022 Oct 14; 23 (20): 12264. DOI: 10.3390/ijms232012264Luboń W, Luboń M, Kotyla P, Mrukwa-Kominek E. Understanding Ocular Findings and Manifestations of Systemic Lupus Erythematosus: Update Review of the Literature. Int J. Mol Sci. 2022 Oct 14; 23 (20): 12264. DOI: 10.3390/ijms232012264Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. British Journal of Ophthalmology. 2016; 100: 135–141.Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. British Journal of Ophthalmology. 2016; 100: 135–141.McMenamin PG. The distribution of immune cells in the uveal tract of the normal eye. Eye (Lond) 1997; 11 (Pt 2): 183–93.McMenamin PG. The distribution of immune cells in the uveal tract of the normal eye. Eye (Lond) 1997; 11 (Pt 2): 183–93.Keino H, Horie S, Sugita S. Immune privilege and eye-derived T-regulatory cells. J. Immunol Res. 2018 May 20; 2018: 1679197. doi: 10.1155/2018/1679197Keino H, Horie S, Sugita S. Immune privilege and eye-derived T-regulatory cells. J. Immunol Res. 2018 May 20; 2018: 1679197. doi: 10.1155/2018/1679197Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384: 1878–1888.Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384: 1878–1888.Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its management. J. Ophthalmol. 2014; 2014: 197675.Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its management. J. Ophthalmol. 2014; 2014: 197675.Yen YC, Weng SF, Chen HA, Lin YS. Risk of retinal vein occlusion in patients with systemic lupus erythematosis: a population-based cohort study. Br. J. Ophthalmol. 2013; 97: 1192–1196.Yen YC, Weng SF, Chen HA, Lin YS. Risk of retinal vein occlusion in patients with systemic lupus erythematosis: a population-based cohort study. Br. J. Ophthalmol. 2013; 97: 1192–1196.Sandhu V, Quan M. SLE and serum complement: causative, concomitant or coincidental? Open Rheumatol J. 2018 Sep 18; 12: 171. doi: 10.2174/1874312901812010171Sandhu V, Quan M. SLE and serum complement: causative, concomitant or coincidental? Open Rheumatol J. 2018 Sep 18; 12: 171. doi: 10.2174/1874312901812010171D’Cruz DP, Houssiau FA, Ramirez G, Baguley E, McCutcheon J, Vianna J. et al. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol. 1991 Aug; 85 (2): 254–61. doi: 10.1111/j.1365–2249.1991.tb05714.xD’Cruz DP, Houssiau FA, Ramirez G, Baguley E, McCutcheon J, Vianna J. et al. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol. 1991 Aug; 85 (2): 254–61. doi: 10.1111/j.1365–2249.1991.tb05714.xRenaudineau Y, Dugu´e C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002 Dec; 1 (6): 365–72. doi: 10.1016/s1568-9972(02)00063-0.12848993Renaudineau Y, Dugu´e C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002 Dec; 1 (6): 365–72. doi: 10.1016/s1568-9972(02)00063-0.12848993Atehortúa L, Rojas M, V´ asquez GM, Castano ˜ D. Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction. Mediat Inflamm. 2017; 2017: 9680729. doi: 10.1155/2017/9680729Atehortúa L, Rojas M, V´ asquez GM, Castano ˜ D. Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction. Mediat Inflamm. 2017; 2017: 9680729. doi: 10.1155/2017/9680729Erkan D, Salmon JE. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk. J. Haematol. 2016 Mar 5; 33 (1): 1–7. doi: 10.4274/tjh.2015.0197Erkan D, Salmon JE. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk. J. Haematol. 2016 Mar 5; 33 (1): 1–7. doi: 10.4274/tjh.2015.0197Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010; 2010: 948364. doi: 10.1155/2010/948364Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010; 2010: 948364. doi: 10.1155/2010/948364Jones Buie JN, Oates JC. Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms. Am. J. Med. Sci. 2014 Aug; 348 (2): 168–75. doi: 10.1097/MAJ.0000000000000284Jones Buie JN, Oates JC. Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms. Am. J. Med. Sci. 2014 Aug; 348 (2): 168–75. doi: 10.1097/MAJ.0000000000000284Knight JS, Kaplan MJ. Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 2012 Sep; 24 (5): 441–50. doi: 10.1097/BOR.0b013e3283546703.22617827Knight JS, Kaplan MJ. Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 2012 Sep; 24 (5): 441–50. doi: 10.1097/BOR.0b013e3283546703.22617827Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U S A. 2010 May 25; 107 (21): 9813–8. doi: 10.1073/pnas.0909927107Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U S A. 2010 May 25; 107 (21): 9813–8. doi: 10.1073/pnas.0909927107Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011 Sep 27; 7 (12): 691–9. doi: 10.1038/nrrheum.2011.132Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011 Sep 27; 7 (12): 691–9. doi: 10.1038/nrrheum.2011.132Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol. 2013 Jul; 35 (4): 455–63. DOI: 10.1007/s00281-013-0375-7Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol. 2013 Jul; 35 (4): 455–63. DOI: 10.1007/s00281-013-0375-7Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 2011 Jul 1; 187 (1): 538–52. doi: 10.4049/jimmunol.1100450Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 2011 Jul 1; 187 (1): 538–52. doi: 10.4049/jimmunol.1100450Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE – Mechanisms and management. Nat. Rev. Rheumatol. 2012 Feb 14; 8 (4): 214–23. doi: 10.1038/nrrheum.2012.14Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE – Mechanisms and management. Nat. Rev. Rheumatol. 2012 Feb 14; 8 (4): 214–23. doi: 10.1038/nrrheum.2012.14Chang PC, Chen WS, Lin HY, Lee HM, Chen SJ. Combined central retinal artery and vein occlusion in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2010 Feb; 19 (2): 206–9. doi: 10.1177/0961203309345751Chang PC, Chen WS, Lin HY, Lee HM, Chen SJ. Combined central retinal artery and vein occlusion in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2010 Feb; 19 (2): 206–9. doi: 10.1177/0961203309345751Wu C, Dai R, Dong F, Wang Q. Purtscher-like retinopathy in systemic lupus erythematosus. Am. J. Ophthalmol. 2014 Dec; 158 (6): 1335–41. doi: 10.1016/j.ajo.2014.09.001Wu C, Dai R, Dong F, Wang Q. Purtscher-like retinopathy in systemic lupus erythematosus. Am. J. Ophthalmol. 2014 Dec; 158 (6): 1335–41. doi: 10.1016/j.ajo.2014.09.001Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C, Escarcega RO, GarciaCarrasco M, Mendez Martinez S, et al. Systemic lupus erythematosus and hypertension. Autoimmun. Rev. 2019 Oct; 18 (10): 102371. doi: 10.1016/j.autrev.2019.102371Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C, Escarcega RO, GarciaCarrasco M, Mendez Martinez S, et al. Systemic lupus erythematosus and hypertension. Autoimmun. Rev. 2019 Oct; 18 (10): 102371. doi: 10.1016/j.autrev.2019.102371Kono S, Takashima H, Suzuki D, Terada T, Konishi T, Miyajima H. Orbital myositis associated with discoid lupus erythematosus. Lupus. 2014 Feb; 23 (2): 220–2. DOI: 10.1177/0961203313517156Kono S, Takashima H, Suzuki D, Terada T, Konishi T, Miyajima H. Orbital myositis associated with discoid lupus erythematosus. Lupus. 2014 Feb; 23 (2): 220–2. DOI: 10.1177/0961203313517156Stavrou P, Murray PI, Batta K, Gordon C. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. Br. J. Ophthalmol. 2002 Apr; 86 (4): 474–5. DOI: 10.1136/bjo.86.4.474Stavrou P, Murray PI, Batta K, Gordon C. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. Br. J. Ophthalmol. 2002 Apr; 86 (4): 474–5. DOI: 10.1136/bjo.86.4.474Mseddi M, Marrekchi S, Meziou TJ, Sellami D, Kammoun B, Feki J, Zahaf A, Turki H. Lupus érythémateux discoïde et paupière. Une série de 9 patients [Discoid lupus erythematosus with eyelid involvement. A series of nine patients]. J. Fr. Ophtalmol. 2007 Mar; 30 (3): 247–9. French. DOI: 10.1016/s01815512(07)89585-4Mseddi M, Marrekchi S, Meziou TJ, Sellami D, Kammoun B, Feki J, Zahaf A, Turki H. Lupus érythémateux discoïde et paupière. Une série de 9 patients [Discoid lupus erythematosus with eyelid involvement. A series of nine patients]. J. Fr. Ophtalmol. 2007 Mar; 30 (3): 247–9. French. DOI: 10.1016/s01815512(07)89585-4Lo Y, Jee SH, Cheng YP. Periorbital heliotrope edema as an uncommon manifestation of juvenile-onset systemic lupus erythematosus. Kaohsiung J. Med. Sci. 2020 Sep; 36 (9): 759–760. DOI: 10.1002/kjm2.12254Lo Y, Jee SH, Cheng YP. Periorbital heliotrope edema as an uncommon manifestation of juvenile-onset systemic lupus erythematosus. Kaohsiung J. Med. Sci. 2020 Sep; 36 (9): 759–760. DOI: 10.1002/kjm2.12254Mullaaziz D., Maden S., Deren O., Özkayalar H. Periorbital lupus erythematosus profundus: A case report and review of the literature. Turkderm. 2020; 54: 114–116.Mullaaziz D., Maden S., Deren O., Özkayalar H. Periorbital lupus erythematosus profundus: A case report and review of the literature. Turkderm. 2020; 54: 114–116.Darjani A, Rafiei R, Mesbah A, Golmohammadi R, Rafiee B, Movaseghi M. Discoid Lupus Erythematosus Presenting as Upper Eyelid Edema and Erythema. Acta Med. Iran. 2017 Jul; 55 (7): 474–476.Darjani A, Rafiei R, Mesbah A, Golmohammadi R, Rafiee B, Movaseghi M. Discoid Lupus Erythematosus Presenting as Upper Eyelid Edema and Erythema. Acta Med. Iran. 2017 Jul; 55 (7): 474–476.Theisen E, Tiao J, Fedeles F. Periorbital discoid lupus erythematosus: A retrospective study. JAAD Case Rep. 2022 Jun 2; 25: 78–82. DOI: 10.1016/j.jdcr.2022.05.024Theisen E, Tiao J, Fedeles F. Periorbital discoid lupus erythematosus: A retrospective study. JAAD Case Rep. 2022 Jun 2; 25: 78–82. DOI: 10.1016/j.jdcr.2022.05.024Kemeny-Beke A, Szodoray P. Ocular manifestations of rheumatic diseases. Int Ophthalmol. 2020 Feb; 40 (2): 503–510. DOI: 10.1007/s10792-019-01183-9Kemeny-Beke A, Szodoray P. Ocular manifestations of rheumatic diseases. Int Ophthalmol. 2020 Feb; 40 (2): 503–510. DOI: 10.1007/s10792-019-01183-9Wang L, Xie Y, Deng Y. Prevalence of dry eye in patients with systemic lupus erythematosus: a meta-analysis. BMJ Open. 2021 Sep 29; 11 (9): e047081. DOI: 10.1136/bmjopen-2020–047081Wang L, Xie Y, Deng Y. Prevalence of dry eye in patients with systemic lupus erythematosus: a meta-analysis. BMJ Open. 2021 Sep 29; 11 (9): e047081. DOI: 10.1136/bmjopen-2020–047081Schonberg S, Stokkermans TJ. Episcleritis. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.Schonberg S, Stokkermans TJ. Episcleritis. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.Dutta Majumder P, Agrawal R, McCluskey P, Biswas J. Current Approach for the Diagnosis and Management of Noninfective Scleritis. Asia Pac J. Ophthalmol (Phila). 2020 Dec 7; 10 (2): 212–223. DOI: 10.1097/APO.0000000000000341Dutta Majumder P, Agrawal R, McCluskey P, Biswas J. Current Approach for the Diagnosis and Management of Noninfective Scleritis. Asia Pac J. Ophthalmol (Phila). 2020 Dec 7; 10 (2): 212–223. DOI: 10.1097/APO.0000000000000341Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999 Mar-Apr; 43 (5): 379–96. DOI: 10.1016/s0039-6257(98)00051-4Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999 Mar-Apr; 43 (5): 379–96. DOI: 10.1016/s0039-6257(98)00051-4Cao Y, Zhang W, Wu J, Zhang H, Zhou H. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol. 2017; 2017: 7298026. DOI: 10.1155/2017/7298026. Epub 2017 Jul 13.Cao Y, Zhang W, Wu J, Zhang H, Zhou H. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol. 2017; 2017: 7298026. DOI: 10.1155/2017/7298026. Epub 2017 Jul 13.Lally L, Sammaritano LR. Vasculitis in antiphospholipid syndrome. Rheum Dis Clin. North. Am. 2015; 41 (1): 109–23, ix. DOI: 10.1016/j.rdc.2014.09.009Lally L, Sammaritano LR. Vasculitis in antiphospholipid syndrome. Rheum Dis Clin. North. Am. 2015; 41 (1): 109–23, ix. DOI: 10.1016/j.rdc.2014.09.009Montehermoso A, Cervera R, Font J, Ramos-Casals M, García-carrasco M, Formiga F, Callejas JL, Jorfán M, Griñó MC, Ingelmo M. Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1999 Apr; 28 (5): 326–32. DOI: 10.1016/s0049–0172(99)80017-1Montehermoso A, Cervera R, Font J, Ramos-Casals M, García-carrasco M, Formiga F, Callejas JL, Jorfán M, Griñó MC, Ingelmo M. Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1999 Apr; 28 (5): 326–32. DOI: 10.1016/s0049–0172(99)80017-1Liu R, Wang Y, Xia Q, Xu T, Han T, Cai S, Luo SL, Wu R, Shao Y. Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach. Quant Imaging Med. Surg. 2022 Jan; 12 (1): 823–837. DOI: 10.21037/qims-21–359Liu R, Wang Y, Xia Q, Xu T, Han T, Cai S, Luo SL, Wu R, Shao Y. Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach. Quant Imaging Med. Surg. 2022 Jan; 12 (1): 823–837. DOI: 10.21037/qims-21–359Radosavljević A, Karadžić J, Kovačević I, Ljikar J, Devečerski G. Severe vaso-occlusive retinopathy associated with systemic lupus erythematosus. Vojnosanit Pregl. 2016 Dec; 73 (12): 1164–7. DOI: 10.2298/VSP150605136RRadosavljević A, Karadžić J, Kovačević I, Ljikar J, Devečerski G. Severe vaso-occlusive retinopathy associated with systemic lupus erythematosus. Vojnosanit Pregl. 2016 Dec; 73 (12): 1164–7. DOI: 10.2298/VSP150605136RLeone P, Prete M, Malerba E, Bray A, Susca N, Ingravallo G, Racanelli V. Lupus Vasculitis : An Overview. Biomedicines. 2021 Nov 5; 9 (11): 1626. DOI: 10.3390/biomedicines9111626Leone P, Prete M, Malerba E, Bray A, Susca N, Ingravallo G, Racanelli V. Lupus Vasculitis : An Overview. Biomedicines. 2021 Nov 5; 9 (11): 1626. DOI: 10.3390/biomedicines9111626Dias-Santos A, Tavares Ferreira J, Pinheiro S, Cunha JP, Alves M, Papoila AL, Moraes-Fontes MF, Proença R. Choroidal thickness changes in systemic lupus erythematosus patients. Clin Ophthalmol. 2019 Aug 20; 13: 1567–1578. DOI: 10.2147/OPTH.S219347Dias-Santos A, Tavares Ferreira J, Pinheiro S, Cunha JP, Alves M, Papoila AL, Moraes-Fontes MF, Proença R. Choroidal thickness changes in systemic lupus erythematosus patients. Clin Ophthalmol. 2019 Aug 20; 13: 1567–1578. DOI: 10.2147/OPTH.S219347Arevalo JF, Lowder CY, Muci-Mendoza R. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2002 Dec; 13 (6): 404–10. DOI: 10.1097/00055735-200212000-00011Arevalo JF, Lowder CY, Muci-Mendoza R. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2002 Dec; 13 (6): 404–10. DOI: 10.1097/00055735-200212000-00011Zink JM, Singh-Parikshak R, Johnson CS, Zacks DN. Hypopyon uveitis associated with systemic lupus erythematosus and antiphospholipid antibody syndrome. Graefes Arch Clin Exp Ophthalmol. 2005 Apr; 243 (4): 386–8. DOI: 10.1007/s00417-004-1022-8Zink JM, Singh-Parikshak R, Johnson CS, Zacks DN. Hypopyon uveitis associated with systemic lupus erythematosus and antiphospholipid antibody syndrome. Graefes Arch Clin Exp Ophthalmol. 2005 Apr; 243 (4): 386–8. DOI: 10.1007/s00417-004-1022-8Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus : a systematic review. Int J. Rheum Dis. 2014 Jun; 17 (5): 494–501. DOI: 10.1111/1756-185X.12337Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus : a systematic review. Int J. Rheum Dis. 2014 Jun; 17 (5): 494–501. DOI: 10.1111/1756-185X.12337de Andrade FA, Guimarães Moreira Balbi G, Bortoloti de Azevedo LG, Provenzano Sá G, Vieira de Moraes Junior H, Mendes Klumb E, Abramino Levy R. Neuro-ophthalmologic manifestations in systemic lupus erythematosus. Lupus. 2017 Apr; 26 (5): 522–528. DOI: 10.1177/0961203316683265de Andrade FA, Guimarães Moreira Balbi G, Bortoloti de Azevedo LG, Provenzano Sá G, Vieira de Moraes Junior H, Mendes Klumb E, Abramino Levy R. Neuro-ophthalmologic manifestations in systemic lupus erythematosus. Lupus. 2017 Apr; 26 (5): 522–528. DOI: 10.1177/0961203316683265Jimenez-Vega A, Herencia-Anaya K, Palacios-Sánchez C, Cáceres-Del-Carpio J. Choroidopathy and optic neuropathy in systemic lupus erythematosus, a case report. Arch Soc Esp Oftalmol (Engl Ed). 2022 Jan; 97 (1): 34–39. DOI: 10.1016/j.oftale.2021.12.001Jimenez-Vega A, Herencia-Anaya K, Palacios-Sánchez C, Cáceres-Del-Carpio J. Choroidopathy and optic neuropathy in systemic lupus erythematosus, a case report. Arch Soc Esp Oftalmol (Engl Ed). 2022 Jan; 97 (1): 34–39. DOI: 10.1016/j.oftale.2021.12.001Nakamagoe K, Yanagiha H, Miyake Z, Kondo Y, Hiyama T, Ishii A, Kaji Y, Oshika T, Sumida T, Tamaoka A. Monocular Oculomotor Nerve Disorder Manifesting as Cranial Neuropathy in Systemic Lupus Erythematosus. Intern Med. 2018 Dec 1; 57 (23): 3445–3449. DOI: 10.2169/internalmedicine.1106-18Nakamagoe K, Yanagiha H, Miyake Z, Kondo Y, Hiyama T, Ishii A, Kaji Y, Oshika T, Sumida T, Tamaoka A. Monocular Oculomotor Nerve Disorder Manifesting as Cranial Neuropathy in Systemic Lupus Erythematosus. Intern Med. 2018 Dec 1; 57 (23): 3445–3449. DOI: 10.2169/internalmedicine.1106-18Conigliaro P, Cesareo M, Chimenti MS, Triggianese P, Canofari C, Barbato C, Giannini C, Salandri AG, Nucci C, Perricone R. Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. Autoimmun Rev. 2019 Mar; 18 (3): 247–254. DOI: 10.1016/j.autrev.2018.09.011Conigliaro P, Cesareo M, Chimenti MS, Triggianese P, Canofari C, Barbato C, Giannini C, Salandri AG, Nucci C, Perricone R. Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. Autoimmun Rev. 2019 Mar; 18 (3): 247–254. DOI: 10.1016/j.autrev.2018.09.011Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017 Jun; 31 (6): 828–845. DOI: 10.1038/eye.2016.298Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017 Jun; 31 (6): 828–845. DOI: 10.1038/eye.2016.298Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017 Apr 1; 56 (suppl_1): i114–i122. DOI: 10.1093/rheumatology/kew406Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017 Apr 1; 56 (suppl_1): i114–i122. DOI: 10.1093/rheumatology/kew406

The authors declare that there are no conflicts of interest present.